Poster Display & Cocktail

30P - Assessing the potential role of RICTOR expression as predictive factor of response to PI3K/mTOR pathway inhibitors in preclinical models of squamous cell lung cancer

Date

02 Mar 2020

Session

Poster Display & Cocktail

Presenters

Anastasios Gkountakos

Citation

Annals of Oncology (2020) 31 (suppl_1): S13-S15. 10.1016/annonc/annonc83

Authors

A. Gkountakos¹, M. Simbolo¹, C. Vicentini², R.T. Lawlor², L. Veghini¹, S. Pilotto³, V. Ludovini⁴, R. Chiari⁴, S. Novello⁵, G. Tortora⁶, M. Milella³, A. Scarpa⁷, V. Corbo⁷, E. Bria⁶

Author affiliations

¹ Department Of Diagnostics And Public Health, Section Of Anatomical Pathology, University and Hospital Trust of Verona, 37134 - Verona/IT
² Arc-net Research Centre, University and Hospital Trust of Verona, Verona/IT
³ Department Of Medicine, Section Of Medical Oncology, University of Verona, AOU Integrata, 37134 - Verona/IT
⁴ Division Of Medical Oncology, S. Maria della Misericordia Hospital, University of Perugia, 06156 - Perugia/IT
⁵ Thoracic Oncology Unit, San Luigi Hospital, University of Turin, 10043 - Orbassano/IT
⁶ Medical Oncology, Università Cattolica Del Sacro Cuore, Comprehensive Cancer Center, Fondazione Policlinico Universitario Agostino Gemelli - IRCCS Rome, 00168 - Rome/IT
⁷ Arc-net Research Centre And Department Of Diagnostics And Public Health, Section Of Anatomical Pathology, University and Hospital Trust of Verona, 37134 - Verona/IT

More

Resources

Login

Abstract 30P

Amplification of RICTOR has been suggested to drive PI3K/mTOR pathway activation in squamous cell lung cancer (SQLC), representing a potential predictive biomarker of response to targeted therapy. Here, we sought to perform a thorough validation of RICTOR as predictive biomarker in SQLC preclinical models before advancing potential intervention strategies to the clinic.

Abstract 30P

Resources from the same session